Precision BioSciences (DTIL) to Release Earnings on Monday

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Precision BioSciences to post earnings of ($0.38) per share and revenue of $5.00 million for the quarter.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by ($1.11). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Up 0.5 %

Shares of NASDAQ:DTIL opened at $5.75 on Monday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $60.66 million, a P/E ratio of 95.85 and a beta of 1.55. Precision BioSciences has a 52-week low of $3.61 and a 52-week high of $13.44. The stock's fifty day simple moving average is $5.03 and its 200-day simple moving average is $5.69.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. BMO Capital Markets upgraded shares of Precision BioSciences from a "market perform" rating to an "outperform" rating and set a $34.00 price target for the company in a report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday, March 28th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.